ASIACARE is a Consultancy and Placement Agency specializing in providing quality homecare support. We are registered in the Province of Ontario. Our clients are foreign-trained nurses, teachers, physiotherapists and caregivers who are interested in relocating temporarily or permanently to Canada. Our goal is to locate qualified and experienced caregivers, including those in the medical health fields, to work with Canadian employers.
Since 1990, Coral Ventures has partnered with entrepreneurs and management teams to build emerging businesses into market leaders in the communications, information technology, media, software and health care sectors. In 2002, the partners from Coral Ventures created two separate industry-focused firms: Coral Capital Management, focused on information technology companies, including media, software and communications, and Thomas, McNerney & Partners, focused on life science and medical technology companies. Coral Ventures and the existing team will continue to manage its investments. New investment opportunities should be directed to Coral Capital Management or Thomas, McNerney & Partners.
Drug Royalty Corporation (DRC) is a privately held healthcare investment company that is a leading purchaser of royalties on commercialized drugs and drugs with near term commercial visibility. DRC also invests capital by acquiring revenue based cash flows from companies within the life-sciences industry and can augment royalty and revenue based investments with equity investments. A pioneer in the field when launched in 1992, DRC was the first firm to acquire royalties in the life sciences sector and the first to complete royalty transactions with inventors and institutions. Since then, DRC has built an impressive international royalty portfolio of blockbuster products including pharmaceutical and medical device technologies.
Picchio Pharma Inc. is a joint venture company established between Dr. Francesco Bellini and Power Technology Investment Corporation, a subsidiary of Power Corporation of Canada. Picchio Pharma's objective is to become a leading Canadian biopharmaceutical company dedicated to acquiring, developing and commercializing new therapeutic products and technologies.
Trevi provides development and growth capital for private healthcare companies with emphasis on medical devices, biopharmaceuticals and healthcare services. The firm was founded in 2005 and has offices in New York and London. The firm typically invests $5 - 10 million in each company. The firm also has strategic affiliations that provide international co-investment opportunities and flexible sources of capital for larger transactions.
If you are ready to take your healthcare company to the next level, CroBern Management Partnership ("CroBern") has a unique combination of capital and operating expertise that can help you get there. u Not only can CroBern provide the capital required for growth, but it also can provide extensive health care industry expertise to help achieve that growth. u CroBern's partners are seasoned executives with a track record of successfully mentoring founders and owners of healthcare firms. u CroBern's partners go at risk themselves and will assist you in the implementation of your growth strategy. u CroBern has invested and successfully worked with all types and sizes of healthcare companies for more than 15 years.
http://www.angelstrategies.com
Angel Strategies provides our angels with two unique value propositions: The first value proposition being that Angel Strategies negotiates founders stock from each company in in exchange for the value we bring. This stock is shared with our angel investors in exchange for their investment dollars. The second value proposition being that Angel Strategies negotiates a "not-to-exceed" valuation with every entrepreneur at the beginning of our process. Thus, as a result of our ASAP program, by the time the company is ready for funding, the "true" valuation is often three times "not-to-exceed" value paid for by our angels. Angel Strategies offers a wide variety of programs and opportunities for everything from the individual angel investor, to the close-knit investor group to the large-scale angel club. Fundamentally, all investors are looking for three important attributes relating to investments.
De Novo Ventures, based in northern California, invests in life science companies primarily based in the western United States. Its targeted areas of interest include medical devices, genomics, biotech/pharmaceuticals, drug delivery, and healthcare Internet. De Novo raised $100 million in the spring of 2000, and invests primarily in seed and early-stage companies. De Novo's team brings years of experience in venture capital investing, entrepreneurism, operating and management roles, and an intimate understanding of the practice of medicine.
Essex Woodlands was founded in 1985 with the establishment of Essex Venture Fund I, LP. Since 1985, the Partnership has raised seven additional funds with nearly $2.5 billion under management, making Essex Woodlands one of the world's largest and most established healthcare venture capital firms. The team is comprised of 23 professionals with principal offices in Palo Alto, Houston, New York and London. This team brings over 300 years of collective healthcare experience. For over 20 years, the firm has maintained its dedicated focus to diversified healthcare investing-primarily serving as lead investor in the founding or the critical financings of over 100 healthcare companies in pharmaceutical, biotechnology, medical device, services and information technology sectors. In addition to its long-standing commitment to early stage companies, the firm has over a decade of experience as a leading late-stage healthcare investor, which includes mature venture, growth equity and PIPE investment opportunities.
http://www.versantventures.com
Versant is committed to transforming healthcare through innovation, and invests in all segments of healthcare including, medical devices, life sciences, healthcare services and healthcare information technology. Within these segments, Versant seeks visionary companies, which target markets where the opportunity exists to make significant and dramatic clinical improvements. As, such, Versant invests in companies with compelling value propositions involving proprietary technology and/or defensible service models. These companies must have highly differentiated products or services that represent substantial innovation over existing practices. While these investments are typically primarily in early stage companies, Versant has and will occasionally invest in later stage companies with the right attributes. Team, Market, Technology, and Business Model are the four most important components Versant Ventures assesses in evaluating companies. We seek seasoned entrepreneurs who have passion, coupled with the requisite skill set, which positions them for success. While we clearly always value teams with deep expertise, we also recognize that early-stage companies rarely have all the expertise they desire. At a minimum, we confirm that the appropriate team might be built if those skills don't already exist. We carefully evaluate teams, and look for positive references from our extensive network of contacts in the healthcare community before we invest in any opportunity. Some of the questions we may evaluate include: Do the leaders possess an in-depth understanding of the business, science, and market opportunities? Do these determined minds have a passion for success and a vision for the future? Are they ready to meet the challenges of building a large company? If there is not sufficient experience, can the team recruit the necessary talent? We seek large market opportunities and will not invest in a new company unless the opportunity has at least $500 million in annualized potential in the US. While it's often difficult to forecast market size, particularly in nascent markets, we still look for a realistic analysis of the size of a market, after segmenting by target customers via both a top-down and bottom-up analysis. Some of the questions we may evaluate include: Is the opportunity targeting an annualized market opportunity greater than $500 million a year? Can the company generate $100 million to $500 million in annual sales? Will the market dynamics encourage rapid adoption of the company's products or services? Who's paying for the product or service?
Psilos has established itself as a successful healthcare investor and has demonstrated its ability to effectively identify and analyze attractive investment opportunities, to structure and consummate high-quality transactions and to work with entrepreneurial management teams from company inception to successful liquidity events. We understand entrepreneurial drive and the importance of developing relationships with companies that reinforce management's creative energies. Psilos seeks investments where we can have a significant positive impact on the strategic development of our portfolio companies, leveraging our broad network of relationships with both strategic and financial investors, corporate partners, investment banks, and industry leaders across the healthcare field. Our team has a multi-disciplinary background and has participated in over 70 healthcare private equity transactions, enabling us to provide meaningful and experienced support to companies around strategy, operations, development of key partnerships, recruitment, marketing, capital formation and merger & acquisition activities.
WELSH, CARSON, ANDERSON & STOWE ("WCAS") is one of the largest and most successful private equity investment firms in the United States. Since our founding in 1979, we have organized 14 limited partnerships with total capital of over $16 billion. We are currently investing Welsh, Carson, Anderson & Stowe X, L.P. ("WCAS X"), a $3.4 billion equity fund, and WCAS Capital Partners IV, L.P., a $1.3 billion dedicated subordinated debt fund. We focus our investment activity exclusively in information/business services and healthcare. Our strategy is to buy growth businesses in our target industries and build value through both internal growth and acquisitions, resulting in superior returns for our investors. We are the largest private equity investor in our two industries. We differentiate ourselves from other private equity firms by our industry specialization, investment track record, operational investment focus, proprietary deal flow, repeat management teams and the experience of our General Partners. Since inception, we have invested in over 150 companies in our core industries and have funded over 650 follow-on acquisitions. Across all WCAS Partnerships, the current portfolio consists of twenty-nine companies with combined revenues of over $22 billion and EBITDA of over $4.5 billion. Our investment experience provides us with an intrinsic knowledge and leadership position within our target industries, allows us to identify, source, close and add value to our investments and, most importantly, provides superior returns to our investors. Our unique combination of investment experience, industry focus, and capital resources allows us to react quickly to prospective new investment opportunities and provide significant strategic and operational value to our portfolio companies. Investors in our previous Partnerships include many of the nation's most prominent institutions, including public and private pension funds, banks, insurance companies, university endowments and other institutional investors. Most of our investors have participated in several WCAS Partnerships.
Privacy Policy | Terms and Conditions | Do Not Sell My Personal Information | Websites Directory
Copyright © 2022 kwtbox.com. All Rights Reserved. US Business Directory